A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Inclusion Criteria: * Written informed consent obtained prior to initiating any trial-specific procedures or assessments. * Male or female patients aged 18 years or over. * Patients with histologically or cytologically confirmed pancreatic adenocarcinoma that is metastatic (stage IV) at diagnosis and who have not received any treatment for their pancreatic cancer. * Patients must be able to receive their first dose of VCN-01 ≤6 weeks after their metastatic pancreatic cancer diagnosis. * Patients must have at least one measurable tumor lesion that can be imaged for assessments according to RECIST 1.1. * ECOG performance status of 0 or 1 at enrollment. * Must be willing to comply with the trial intervention, including prophylactic medications, and procedures. * Adequate baseline organ function (hematologic, liver, renal) within the 7 days prior to enrollment: Hematology: * Leukocytes ≥3.0x103 mcL * Absolute neutrophil count ≥1.5x10⁹/L * Hemoglobin ≥9 g/dL * Platelets ≥100x10⁹/L Coagulation: * Prothrombin time or international normalized ratio ≤1x upper limit of normal (ULN) * Activated partial thromboplastin time ≤1.2xULN Hepatic: * Total bilirubin ≤1.5xULN * ALT and AST ≤2.5xULN (\<5xULN is acceptable if liver metastases are present) Renal: * Serum creatinine ≤1.5xULN; or, * If serum creatinine \>1.5xULN, an estimated creatinine clearance \>50 mL/min using the Cockcroft and Gault formula Nutritional: • Serum Albumin ≥30 g/L \- Adequate left ventricular ejection fraction (LVEF) ≥ 50% measured by ECHO or MUGA and QT interval corrected by Fridericia (QTcF) assessment ≤ 450 ms for men or ≤ 470 ms for women. Exclusion Criteria: * Unwillingness to complete the trial procedures for geographic, psychiatric, or social reasons. * Patient has previously received treatment for their metastatic pancreatic cancer with surgery, radiotherapy, chemotherapy or investigational therapy; except that: * Palliative radiotherapy for pain is permitted; * Placement of a biliary stent/tube is permitted. * Patients who, in the opinion of the investigator, have symptoms or signs suggesting clinically unacceptable deterioration during the Screening Period. * Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes: • Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice. * Patients with past or resolved TB are eligible to participate. • Hepatitis B Virus (HBV; positive HBV surface antigen \[HBsAg\] result). * HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate; * Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate; * Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[HBcAb\] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment. • Hepatitis C Virus (HCV; positive HCV Ribonucleic acid \[RNA\]). * Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate; * Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA). * Human immunodeficiency virus (positive HIV 1/2 antibodies) Active infection or other serious illness or autoimmune disease at the moment of enrollment. Active infection includes: * Tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice. \- Patients with past or resolved TB are eligible to participate. * Hepatitis B Virus (HBV; positive HBV surface antigen \[HBsAg\] result). * HBV carriers (patients positive for HBsAg without an active infection) are not eligible to participate; * Patients requiring antiviral medicines for HBV prophylaxis or treatment are not eligible to participate; * Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \[HBcAb\] and absence of HBsAg) are eligible to participate provided that blood HBV DNA is negative at enrollment. * Hepatitis C Virus (HCV; positive HCV Ribonucleic acid \[RNA\]). * Patients requiring antiviral medicines for HCV prophylaxis or treatment are not eligible to participate; * Patients positive for HCV antibody are eligible to participate (only if polymerase chain reaction is negative for HCV RNA). * Human immunodeficiency virus (positive HIV 1/2 antibodies) * Known chronic liver disease (e.g. liver cirrhosis, liver fibrosis, chronic hepatitis); except that: * Patients with fatty liver disease are eligible to participate if their liver transaminases meet inclusion criterion 8. * Concurrent malignant hematologic or solid disease; except that: * Patients with a prior history of cancer are eligible to participate if they are in complete remission from their prior cancer for at least 3 years. * Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency. * Patients with untreated brain metastases and/or leptomeningeal carcinomatosis with progressive symptoms despite corticosteroid coverage; except that: * Patients with brain metastases with stable symptoms are eligible to participate. * Patients with previous pneumonitis or interstitial lung disease. * Patients with pre-existing sensory neuropathy \>G1 * Clinical evidence of deep vein thrombosis, pulmonary embolism or arterial thromboembolic event during the Screening Period. * Patients with superficial vein thrombosis are eligible to participate. * Patients with uncontrolled coagulopathy. * Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical trial due to concerns over safety or potential non-compliance with clinical trial procedures. * A female patient, who is pregnant or lactating. * Female patients of reproductive potential must agree to use a highly effective method of birth control. Male patients must agree to use condoms. * Treatment with live attenuated vaccines in the last 3 weeks before the administration of the IMP. * Treatment with an adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of the IMP. * Treatment with another investigational agent within five of that investigational agent's half-lives prior to the administration of the IMP. * Chronic immunosuppressive therapy; except that: * Inhaled corticosteroids are permitted; * Oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day are permitted; * Dexamethasone up to a maximum dose of 1 mg/day is permitted. * Known allergy or hypersensitivity to any of the trial-specific interventions or any of their excipients. * Subjects, for whom first line treatment options other than the combination nab-paclitaxel/gemcitabine are recommended by the investigator.